ResearcherHumanitas UniversityActive in the last 2 years

Diego Palumbo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7906-540X; OpenAlex author ID A5060960760. Sources: OpenAlex.

Their work

Papers: 16
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 66

Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 7 papers

Papers 16

Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716 ↗
Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015 ↗
Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190 ↗
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x ↗
Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-026-09467-z ↗
Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8 ↗
ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1 ↗
Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033 ↗
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006 ↗
Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.02.005 ↗
Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2 ↗
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152 ↗
Limited impact of discretization/interpolation parameters on the predictive power of CT radiomic features in a surgical cohort of pancreatic cancer patients. Co-author DOI 10.1007/s11547-023-01649-y ↗
The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771 ↗
Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087 ↗
Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Co-author DOI 10.3390/cancers13194938 ↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.